Even though the biotech group is off 9 percent in the last 6 weeks, companies and bankers apparently believe that the market is ready to accept IPO paper, as four sizable deals now stand in the queue.

On the heels of Tularik Inc.'s IPO filing to raise up to $81.25 million, Maxygen Inc., a developer of DNA-shuffling technology, filed to raise up to $80.5 million in its IPO. Other deals include "lab-on-a-chip" developer Caliper Technologies Corp., which filed to raise up to $60 million, and combinatorial materials science play Symyx Technologies Inc., which is looking to raise up to $69 million.